HRT and breast cancer risk: what studies really say

In brief

• Breast cancer risk exists, especially with estrogen-progestogen treatments, and it increases with the duration of exposure.
• Not all MHT is equal: the type of progestogen significantly alters the risk profile, as shown by the E3N study.
• Estrogen-only treatments have a different profile but are reserved for hysterectomized women.
• No woman is left without options: non-hormonal alternatives, lifestyle adjustments, and targeted cryotherapy with Héra for immediate relief.

You have read everything and its opposite regarding menopausal hormone therapy. That it protects. That it threatens. That the risk of breast cancer climbs, that it remains tiny, that it depends on the progestogen. The result: you no longer know what to believe.

Rest assured, you are not alone in this fog. MHT and the risk of breast cancer form one of the most poorly explained topics in women's health. This article will not decide for you—your doctor will do that, with you. Its goal is more useful: to give you the numbers, the nuances, and the questions to ask so you can arrive prepared for your consultation.

Because yes, the answer is neither "it's dangerous" nor "it's risk-free." It is more subtle than that, and it often hinges on details no one has explained to you.

Essential reminder: this content is for information purposes only. It never replaces the advice of your doctor or gynecologist. MHT should neither be started nor stopped without consulting them.

What exactly is MHT?

Menopausal Hormone Therapy—also called Hormone Replacement Therapy (HRT) or MHT—replaces the hormones your ovaries no longer produce: estrogens and, depending on the case, progesterone. It has one single goal: to relieve symptoms that are disruptive enough to affect your daily life.

Note that this is not a preventive treatment. It is not prescribed "to stay young" or to avoid a disease. It is prescribed when climacteric symptoms alter quality of life, at the lowest dose and for the shortest duration possible. The French National Authority for Health (HAS) clearly reiterates this in its recommendations on menopausal hormone treatments.

Estrogen-only or estrogen-progestogen: two different situations

Everything depends first on whether you have a uterus.

• Estrogen-only: reserved for women who have had a hysterectomy. Without a uterus, the risk of endometrial cancer disappears, and their breast profile appears more favorable than that of combined treatments.
• Estrogen-progestogen: for women who still have their uterus. Progestogen is necessary to protect the endometrium from the effects of estrogen. However, it is also this progestogen—and its specific type—that is associated with increased breast risk.

In other words: the presence of a progestogen, and the progestogen chosen, matter as much as the estrogen. This is the primary key to understanding it.

Oral or transdermal route: what really changes

With the oral route, the medication passes through the liver before reaching the bloodstream. With the transdermal route—patch or gel—it enters the blood directly, without this "first-pass metabolism." This detail has consequences, but not necessarily the ones you might imagine.

What is established: the transdermal route reduces certain risks, notably that of venous thrombosis. What is not: that it reduces the risk of breast cancer. The current data does not allow us to confirm this, as confirmed by the NICE menopause guideline. The choice of route should therefore be discussed based on criteria other than breast protection.

What major studies say

Three bodies of work consistently recur in conversations. They do not say exactly the same thing—and that is precisely where the misunderstandings arise.

The WHI study: the bombshell of the 2000s

The Women's Health Initiative is one of the largest clinical trials ever conducted on menopause. In 2002, one of its components was stopped prematurely: among women taking estrogen + progestogen, the risk of invasive breast cancer had increased.

The numbers, in summary:

• Estrogen + progestogen: relative risk of approximately 1.24, or about 41 cases per 10,000 women-years versus 33 for non-users. Prolonged follow-up confirmed an increase in incidence.
• Estrogen-only (in hysterectomized women): no increase observed during the trial. After more than 20 years of follow-up, the incidence was even lower in this group. The details of these results can be consulted on the National Cancer Institute website.

Be careful not to turn this last point into a promise. This result concerns a specific population and a specific treatment. It does not prove that estrogen protects against breast cancer.

The Million Women Study: duration changes everything

This British observational study followed more than a million women aged 50 to 64. A striking result: among users at the time of the study, the risk of invasive breast cancer was increased. For combined treatments, the relative risk reached approximately 2. For estrogen-only, approximately 1.30. The original work was published in The Lancet in 2003.

The most telling figure concerns duration: 10 years of treatment were associated with about 5 additional cases per 1,000 users of estrogen-only, and about 19 per 1,000 on combined treatment, again compared to women who had never taken MHT.

This is an observational study. It describes an association within a population, not the individual risk of each woman.

The E3N cohort: the question of progestogen

The French E3N study, led by Inserm, followed approximately 100,000 women. An analysis of 80,377 postmenopausal women compared risks based on the type of hormones used. Here is what it shows:

• Estrogen + progesterone (similar to natural progesterone): no significant increase, relative risk of 1.00.
• Estrogen + dydrogesterone: 1.16.
• Estrogen + other progestogens: 1.69 on average.
• Estrogen-only: 1.29 in this analysis.

In other words, not all MHT is equal. This French nuance is essential, and it is likely the most poorly reported. You can consult the E3N study and its detailed analysis, as well as the summary from the National Cancer Institute on menopausal hormone treatments and their risks.

The risk reportedly increases especially beyond 5 years of treatment.

Who is concerned by an increased risk?

MHT does not act the same way depending on your personal history. The factors that carry the most weight:

1. A family history of breast cancer, especially in a mother, sister, or daughter.
2. A genetic predisposition, such as a BRCA1 or BRCA2 mutation.
3. Treatment duration: risk climbs with years of exposure.
4. Age of onset and the time of life when treatment begins.
5. The type of progestogen combined with estrogen.

Conversely, known or suspected breast cancer, as well as estrogen-dependent tumors, constitute a contraindication to MHT.

The key point: these factors should not be read in isolation. It is their combination, within your medical file, that guides the medical decision. A family history does not automatically condemn MHT—it requires a more in-depth evaluation, sometimes including an oncogenetic consultation.

The benefits of MHT to weigh in the balance

A real choice is always made with two sides of the scale. MHT does not only have drawbacks, otherwise, it would have been abandoned long ago.

Hot flashes and night sweats. MHT remains the most effective management for moderate-to-severe vasomotor symptoms. This is an important benchmark: nothing else works as well.

Osteoporosis prevention. In some women, MHT is recognized for its protective effect on bone density and the reduction of fracture risk. It is one of the rare treatments that acts on both daily comfort and bone health.

Quality of life. When nights fall apart, concentration slips, and hot flashes happen back-to-back at work, the impact is not a detail. MHT can significantly reduce this in women who tolerate it well.

This is where the pros and cons of MHT come into play: no decision is "right" in the absolute, everything depends on your personal balance.

What to do if MHT is not for you?

You have a contraindication, a personal history, or simply the conviction that you do not want hormones. You are not without solutions—far from it.

Non-hormonal options

Several non-hormonal treatments have evidence of efficacy, with a generally more moderate effect than MHT:

• Certain low-dose antidepressants: useful especially if anxiety or low mood are added factors. Watch out for possible interactions with tamoxifen.
• Gabapentin: interesting when hot flashes disrupt sleep.
• Fezolinetant: a non-hormonal medication that targets central temperature regulation, under hepatic monitoring.
• Cognitive-behavioral therapies adapted for menopause: they primarily reduce discomfort and the impact on daily life. Clinical hypnosis has also shown benefits.

Conversely, clonidine is often disappointing. Supplements based on red clover, black cohosh, or soy do not have sufficiently proven efficacy and can interact with other treatments. For everything related to plants, our article on sage and menopause details what research says—and does not say.

Lifestyle adjustments

They do not replace a treatment, but they change the landscape.

• Identify your triggers: heat, spices, alcohol, stress, coffee. Noting them for a few weeks is often enough to see a pattern.
• Move regularly, stabilize your weight, and regularize your sleep.
• Ventilate, layer clothing, keep the bedroom cool. This is not a treatment, but it reduces daily discomfort.

Our complete guide on hot flashes without hormones: natural solutions delves into these avenues, one by one.

Targeted cryotherapy: immediate relief

There is another angle, rarely mentioned in consultations: acting on the discomfort the very moment it strikes.

Targeted cryotherapy applies controlled cold to a thermosensitive area—the nape of the neck, face, chest, or wrists. The cold stimulates cutaneous thermoreceptors, which send a signal to the hypothalamus. The result: the sensation of heat stops within seconds.

This is the approach of Héra, the portable device from Athana: cold adjustable to several intensities, without hormones or medication. It does not replace a long-term treatment, and it does not claim to treat any disease: it is a wellness device, not a medical device. It acts where MHT and other options often leave a void: the waiting time between two hot flashes, at any time of day.

You can discover the Héra device and how it works. And to understand the entire mechanics of the symptom, our article everything you need to know about menopausal hot flashes details what is happening in the body.

How to talk about it with your doctor

Arrive with written questions. A consultation goes by quickly, and a list prevents forgetting anything.

Ask:

• Is my MHT estrogen-only or estrogen-progestogen? And why this choice?
• Which progestogen is being used, and why that one over another?
• What dose, what route, and for what planned duration?
• Given my personal and family history, how do you evaluate my risk?
• Is an oncogenetic consultation indicated for me?
• What alternative is there if I prefer to avoid hormones?

Regarding breast monitoring: remember that MHT does not exempt you from any screening. Organized breast cancer screening concerns women aged 50 to 74. In cases of significant family history or high risk, personalized monitoring may be necessary, sometimes including MRI and mammography, decided by a specialized team—see the screening modalities for high-risk women and the INCa recommendations for referring patients. Ask if your screening is up to date: it's a simple question that changes a lot.

Finally, the golden rule: reevaluate the benefit/risk ratio at least once a year. Today's situation will not be the same as it is in three years.

⚠️ Medical warning

This article is provided for information purposes only. It does not replace medical advice. Menopausal hormone therapy should never be started, modified, or stopped without the advice of your doctor or gynecologist. The figures cited are averages observed in populations of women: they do not predict your individual risk, which only a healthcare professional can assess with you, based on your history. Héra is a wellness device: it is not intended to diagnose, treat, or cure any disease.

FAQ - Your most frequent questions

Does MHT really increase the risk of breast cancer?

Yes, for estrogen-progestogen treatments, and the increase depends primarily on the duration and the type of progestogen. For estrogen-only, in hysterectomized women, the excess risk was not found in the same way. The risk is real, but it often remains low in absolute value. Only your doctor can weigh it against your situation.

Until what age can MHT be taken?

There is no cut-off age. We aim for the lowest effective dose, for the shortest duration possible, with a re-evaluation at least once a year. In practice, HRT is often started around menopause, and the question of continuing it is revisited every year. Some evidence suggests that starting in the years following menopause is more favorable than resuming it later. The decision is always made on a case-by-case basis.

What are the side effects of HRT?

The most common side effects are breast tenderness, bleeding, bloating, weight gain, mood swings, and irritability. Those related to progestin are often the most noticeable. There are also more serious risks - thrombosis, and breast, endometrial, and ovarian cancers - which depend on the route of administration, the treatment, and your individual profile. Report any unusual symptoms to your doctor.

Can you take HRT after breast cancer?

No. Known or suspected breast cancer is a contraindication for HRT. In such cases, non-hormonal options are used, and breast screening is increased. Consultation with the oncology team is essential before making any decision.

Is a "bio-identical" HRT safer?

There is no clear evidence to that effect. The terms "bio-identical" or "natural" do not mean "risk-free." In France, some formulations are better studied than others, notably progesterone and dydrogesterone, which were associated with a lower increased risk in the E3N study. This does not make the risk zero. Be wary of claims of safety.

Can hot flashes be relieved without hormones?

Yes. Some non-hormonal prescription treatments, cognitive behavioral therapies, hypnosis, and lifestyle adjustments are truly helpful. And for immediate discomfort, targeted cryotherapy with Héra soothes the sensation of heat in seconds. This never replaces medical advice, but it does change your day-to-day life.

In honor of Pink October, Athana is partnering with RoseUp, an association committed to supporting women affected by cancer. This collaboration is particularly meaningful to us, as some women may also face climacteric symptoms during or after their treatments.

Throughout the month of October, €5 will be donated to RoseUp for every Héra purchased.

Discover Héra

Sources

• National Cancer Institute - Menopausal Hormone Therapy and Cancer : cancer.gov
• Million Women Study - The Lancet (2003) : pubmed.ncbi.nlm.nih.gov
• E3N Cohort - analysis of various MHT and breast cancer risk : inserm.hal.science
• National Cancer Institute (France) - Menopausal hormonal treatments : cancer.fr
• HAS - Menopausal hormonal treatments : has-sante.fr
• HAS - Breast cancer screening for high-risk women : has-sante.fr
• INCa - Guiding your patients toward breast cancer screening : cancer.fr
• NICE - Menopause: identification and management (NG23) : nice.org.uk